Articles

One-Year Clinical Outcomes of Ultra Long Apollo Polymer-Based Paclitaxel-Eluting Stents in Patients with Complex, Long Coronary Artery Lesions

Abstract

Background: For all the wealth of research comparing the efficacy of the different types of the drug-eluting stent (DES) such as sirolimus- , paclitaxel- , and zotarolimus-eluting stents, there is still a dearth of data on the different brands of each DES type. We aimed to investigate the one-year clinical outcomes, including major adverse cardiac events (MACE), of the use of the ultra long Apollo paclitaxel-eluting stent in patients with long atherosclerotic coronary artery lesions.
Methods: According to a retrospective review of the Tehran Heart Center Registry of Interventional Cardiology, a single-center nonrandomized computerized data registry in which all adult patients who undergo single or multi-vessel percutaneous coronary intervention (PCI) are enrolled without any specific exclusion criteria, the mixed use of long Apollo paclitaxel-eluting stents and other types of the DES as well as myocardial infarction within forty-eight hours prior to the procedure was excluded. In total, 122 patients were enrolled in the study, and their baseline clinical, angiographic, and procedural characteristics were obtained. In addition, the patients’ follow-up data and, most importantly, MACE during a one-year period after intervention were recorded.
Results: The mean follow-up duration was 14.1 ± 3.8 months. The one-year clinical follow-up data were obtained in 95.9 % of all the patients. The incidence of MACE was 5.7% during the entire study period. There was 1 death, which occurred during the initial days after PCI. The incidence of non-fatal myocardial infarction was 2.5% (3 cases), including one patient who underwent target vessel revascularization seven months later. Also, 3 patients with single-vessel disease and in-stent restenosis underwent coronary artery bypass grafting between five to ten months later.
Conclusions: Our results showed that the Apollo paclitaxel-eluting stent might be regarded as a safe and effective treatment for long coronary lesions.

Files
IssueVol 6 No 3 (2011): J Teh Univ Heart Ctr QRcode
SectionArticles
Keywords
Angioplasty Drug-eluting stents Coronary artery disease Treatment outcome

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Salarifar M, Kassaian SE, Alidoosti M, Haji-Zeinali AM, Poorhoseini HR, Nematipour E, Amirzadegan A, Saroukhani S. One-Year Clinical Outcomes of Ultra Long Apollo Polymer-Based Paclitaxel-Eluting Stents in Patients with Complex, Long Coronary Artery Lesions. J Tehran Heart Cent. 1;6(3):138-142.